The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging.

[1]  G. Jennings,et al.  Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-&ggr; Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation , 2003, Circulation.

[2]  P. Libby,et al.  Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.

[3]  Jasmine Chen,et al.  Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[4]  P. Libby,et al.  Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[5]  T. Warner,et al.  Intimal Smooth Muscle Cells as a Target for Peroxisome Proliferator-Activated Receptor-&ggr; Ligand Therapy , 2002, Circulation research.

[6]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[7]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[8]  Zahi A Fayad,et al.  Progression and Regression of Atherosclerotic Lesions: Monitoring With Serial Noninvasive Magnetic Resonance Imaging , 2002, Circulation.

[9]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[10]  J. Fruchart.  Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism☆ , 2001 .

[11]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[12]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[13]  K R Maravilla,et al.  Effects of Prolonged Intensive Lipid-Lowering Therapy on the Characteristics of Carotid Atherosclerotic Plaques In Vivo by MRI: A Case-Control Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[14]  V. Fuster,et al.  Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging , 2001, Circulation.

[15]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[16]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  V. Fuster,et al.  Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. , 2001, Journal of the American College of Cardiology.

[18]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[19]  W. Hsueh,et al.  Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. , 2001, Diabetes care.

[20]  D. Altshuler,et al.  The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. , 2001, Nature medicine.

[21]  J. Fruchart.  Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. , 2001, The American journal of cardiology.

[22]  D. Altshuler,et al.  The role of PPAR-γ in macrophage differentiation and cholesterol uptake , 2001, Nature Medicine.

[23]  T. Akasaka,et al.  Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. , 2000, Journal of the American College of Cardiology.

[24]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[25]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[26]  S. Midorikawa,et al.  Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. , 2000, Metabolism: clinical and experimental.

[27]  V. Fuster,et al.  Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis. , 2000, Circulation.

[28]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[29]  usso,et al.  EFFECT OF HMG-CoA REDUCTASE INHIBITORS ON CORONARY ARTERY DISEASE AS ASSESSED BY ELECTRON-BEAM COMPUTED TOMOGRAPHY , 2000 .

[30]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[31]  P. Libby,et al.  MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[32]  Zahi A Fayad,et al.  Acute coronary syndromes: biology , 1999, The Lancet.

[33]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[34]  T. Watanabe,et al.  Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. , 1999, Biochemical and biophysical research communications.

[35]  C Yuan,et al.  Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. , 1998, Circulation.

[36]  E A Fisher,et al.  Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. , 1998, Circulation.

[37]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[38]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[39]  P. Libby,et al.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.

[40]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[41]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[42]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit: impact of statin trials. , 1998, Circulation.

[43]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[44]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[45]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[46]  B. Seed,et al.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. , 1998, Nature.

[47]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit. A new look at old data. , 1995, Circulation.

[48]  Chun Yuan,et al.  Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo , 1995, Nature Medicine.

[49]  P. Libby,et al.  Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.